236 related articles for article (PubMed ID: 20842031)
1. Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy.
Capala J; Bouchelouche K
Curr Opin Oncol; 2010 Nov; 22(6):559-66. PubMed ID: 20842031
[TBL] [Abstract][Full Text] [Related]
2. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
Okarvi SM; AlJammaz I
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
[TBL] [Abstract][Full Text] [Related]
3. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.
Sörensen J; Sandberg D; Sandström M; Wennborg A; Feldwisch J; Tolmachev V; Åström G; Lubberink M; Garske-Román U; Carlsson J; Lindman H
J Nucl Med; 2014 May; 55(5):730-5. PubMed ID: 24665085
[TBL] [Abstract][Full Text] [Related]
4. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted
Ulaner GA; Carrasquillo JA; Riedl CC; Yeh R; Hatzoglou V; Ross DS; Jhaveri K; Chandarlapaty S; Hyman DM; Zeglis BM; Lyashchenko SK; Lewis JS
Radiology; 2020 Aug; 296(2):370-378. PubMed ID: 32515679
[TBL] [Abstract][Full Text] [Related]
5. Development of
Rainone P; Riva B; Belloli S; Sudati F; Ripamonti M; Verderio P; Colombo M; Colzani B; Gilardi MC; Moresco RM; Prosperi D
Int J Nanomedicine; 2017; 12():3447-3461. PubMed ID: 28496321
[TBL] [Abstract][Full Text] [Related]
6. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
[TBL] [Abstract][Full Text] [Related]
7. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
Ulaner GA; Hyman DM; Ross DS; Corben A; Chandarlapaty S; Goldfarb S; McArthur H; Erinjeri JP; Solomon SB; Kolb H; Lyashchenko SK; Lewis JS; Carrasquillo JA
J Nucl Med; 2016 Oct; 57(10):1523-1528. PubMed ID: 27151988
[TBL] [Abstract][Full Text] [Related]
8. PET imaging of a
Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
[TBL] [Abstract][Full Text] [Related]
9. Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides.
Ge S; Li J; Yu Y; Chen Z; Yang Y; Zhu L; Sang S; Deng S
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770887
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P
Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging.
Chernomordik V; Hassan M; Lee SB; Zielinski R; Gandjbakhche A; Capala J
Mol Imaging; 2010 Aug; 9(4):192-200. PubMed ID: 20643022
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors.
Altai M; Varasteh Z; Andersson K; Eek A; Boerman O; Orlova A
Cancer Biother Radiopharm; 2013 Apr; 28(3):187-95. PubMed ID: 23461385
[TBL] [Abstract][Full Text] [Related]
14. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
[TBL] [Abstract][Full Text] [Related]
15. Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer.
Goldstein R; Sosabowski J; Vigor K; Chester K; Meyer T
Expert Rev Anticancer Ther; 2013 Mar; 13(3):359-73. PubMed ID: 23477521
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
17. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
18. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Ulaner GA; Hyman DM; Lyashchenko SK; Lewis JS; Carrasquillo JA
Clin Nucl Med; 2017 Dec; 42(12):912-917. PubMed ID: 28872549
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]